235 related articles for article (PubMed ID: 25430674)
1. The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.
Badreldin W; Krell J; Chowdhury S; Harland SJ; Mazhar D; Harding V; Frampton AE; Wilson P; Berney D; Stebbing J; Shamash J
BJU Int; 2016 Mar; 117(3):418-23. PubMed ID: 25430674
[TBL] [Abstract][Full Text] [Related]
2. A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours.
Shamash J; Powles T; Mutsvangwa K; Wilson P; Ansell W; Walsh E; Berney D; Stebbing J; Oliver T
Ann Oncol; 2007 May; 18(5):925-30. PubMed ID: 17355956
[TBL] [Abstract][Full Text] [Related]
3. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.
Selle F; Wittnebel S; Biron P; Gravis G; Roubaud G; Bui BN; Delva R; Bay JO; Fléchon A; Geoffrois L; Caty A; Soares DG; de Revel T; Fizazi K; Gligorov J; Micléa JM; Dubot C; Provent S; Temby I; Gaulet M; Horn E; Brindel I; Lotz JP
Ann Oncol; 2014 Sep; 25(9):1775-1782. PubMed ID: 24894084
[TBL] [Abstract][Full Text] [Related]
5. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
6. Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors.
Nakamura T; Ueda T; Oishi M; Nakanishi H; Fujihara A; Naya Y; Hongo F; Kamoi K; Okihara K; Miki T
Int J Urol; 2015 Mar; 22(3):288-93. PubMed ID: 25393104
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.
Farmakis D; Pectasides M; Pectasides D
Eur Urol; 2005 Sep; 48(3):400-7. PubMed ID: 15964136
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.
Bokemeyer C; Oechsle K; Honecker F; Mayer F; Hartmann JT; Waller CF; Böhlke I; Kollmannsberger C;
Ann Oncol; 2008 Mar; 19(3):448-53. PubMed ID: 18006893
[TBL] [Abstract][Full Text] [Related]
9. Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience.
De Pasquale MD; D'Angelo P; Crocoli A; Boldrini R; Conte M; Bisogno G; Spreafico F; Inserra A; Biasoni D; Dall'Igna P; Siracusa F; Miele E; Terenziani M
Pediatr Blood Cancer; 2020 Mar; 67(3):e28125. PubMed ID: 31850649
[TBL] [Abstract][Full Text] [Related]
10. Salvage chemotherapy with gemcitabine plus oxaliplatin for patients with testicular germ cell cancer.
Uchida M; Kawai K; Kimura T; Ichioka D; Takaoka E; Suetomi T; Miyazaki J; Nishiyama H
Int J Clin Oncol; 2014 Dec; 19(6):1112-7. PubMed ID: 24647526
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Aravantinos G; Nikolaou M; Koumpou M; Gaglia A; Kostopoulou V; Mylonakis N; Economopoulos T; Raptis SA
Eur Urol; 2004 Aug; 46(2):216-21. PubMed ID: 15245816
[TBL] [Abstract][Full Text] [Related]
12. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group.
Seidel C; Oechsle K; Lorch A; Dieing A; Hentrich M; Hornig M; Grünwald V; Cathomas R; Meiler J; de Wit M; Bokemeyer C
Urol Oncol; 2016 Apr; 34(4):167.e21-8. PubMed ID: 26699830
[TBL] [Abstract][Full Text] [Related]
14. Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis.
Hartmann JT; Einhorn L; Nichols CR; Droz JP; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Schmoll HJ; Kanz L; Bokemeyer C
J Clin Oncol; 2001 Mar; 19(6):1641-8. PubMed ID: 11250992
[TBL] [Abstract][Full Text] [Related]
15. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
Kollmannsberger C; Rick O; Derigs HG; Schleucher N; Schöffski P; Beyer J; Schoch R; Sayer HG; Gerl A; Kuczyk M; Spott C; Kanz L; Bokemeyer C
J Clin Oncol; 2002 Apr; 20(8):2031-7. PubMed ID: 11956262
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies.
Nishikawa M; Miyake H; Fujisawa M
Int J Clin Oncol; 2016 Feb; 21(1):162-7. PubMed ID: 26123313
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors.
Oechsle K; Kollmannsberger C; Honecker F; Mayer F; Waller CF; Hartmann JT; Boehlke I; Bokemeyer C;
Eur Urol; 2011 Oct; 60(4):850-5. PubMed ID: 21704446
[TBL] [Abstract][Full Text] [Related]
18. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
Mulherin BP; Brames MJ; Einhorn LH
Am J Clin Oncol; 2015 Aug; 38(4):373-6. PubMed ID: 26214082
[TBL] [Abstract][Full Text] [Related]
20. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.
Lorch A; Bascoul-Mollevi C; Kramar A; Einhorn L; Necchi A; Massard C; De Giorgi U; Fléchon A; Margolin K; Lotz JP; Germà-Lluch JR; Powles T; Kollmannsberger C; Beyer J
J Clin Oncol; 2011 Jun; 29(16):2178-84. PubMed ID: 21444870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
